Welcome back to Healthy Innovations! 👋
This week, we’re diving into the fast-moving world of hearing innovation.
More than 1.5 billion people live with some degree of hearing loss – and 2026 has been a milestone year: the first FDA-approved gene therapy for genetic hearing loss, a new wave of AI-powered hearing aids, and lower-cost access models that could put better hearing within reach for more people.
Let’s dive in.
Our ability to hear is precious. Untreated hearing loss can have a devastating impact on people's ability to communicate, to study and to earn a living. It can also impact on people's mental health and their ability to sustain relationships.
A first-of-its-kind FDA approval
Two-year-old Miles was born profoundly deaf. He was a happy toddler, but he had trouble interacting with his older siblings and showed little interest in music or story time. Genetic testing found the cause of his deafness: a mutation in a gene called OTOF.
In May 2025, as part of a clinical trial, surgeons at Boston Children's Hospital delivered a one-time gene therapy into both of Miles's ears. About a month later, his mother Kerri noticed something new: Miles covered his ears when an ambulance went by. He could hear the siren.
That therapy, now called Otarmeni, won FDA approval in April this year, the first gene therapy ever cleared for genetic hearing loss. In the trial, 16 of 20 children showed measurable improvement within five months, and five of the 12 followed for at least 11 months had hearing essentially restored to normal. By Regeneron's own estimate, OTOF mutations cause roughly 1 to 3% of genetically caused hearing loss at birth, affecting an estimated 50 babies born in the US each year.
Miles and his mom, Kerri, laugh with Eliot Shearer, MD, PhD. Image source: Boston Children’s Hospital
Otarmeni delivers a healthy copy of OTOF directly into the cochlea, restoring production of otoferlin, a protein that relays sound signals from the inner ear's hair cells to the brain. It's given through a surgical procedure similar to cochlear implantation.
Otarmeni was developed originally by Decibel Therapeutics and brought to approval by Regeneron, which acquired the smaller company in 2023.
Regeneron is providing it free to eligible patients in the US, breaking from the usual pattern of pricing one-time rare-disease gene therapies at a premium.
A related gene therapy from Eli Lilly's Akouos program, first given to an 11-year-old boy in Philadelphia in 2023 who had never heard a sound in his life, produced similar results and remains in trials.
At Boston Children's, researchers are already testing gene therapy strategies for other inherited causes of deafness, including mutations in TMC1, stereocilin, TMPRSS3, and the genes behind Usher syndrome, using a two-vector delivery method for genes too large to fit into a single viral carrier.
Hearing aids: the quiet AI upgrade
Globally, more than 1.5 billion people live with some degree of hearing loss, according to the World Health Organization (WHO). For many of them, the most relevant technology isn’t a breakthrough therapy but something far more familiar: the hearing aid – which has quietly evolved into an AI device.
Take Kristi Timmons, a Nashville music lover who spent two decades watching her world shrink as her hearing faded. She stopped going to concerts and avoided noisy rooms. A modern AI-powered hearing aid changed that: it filters speech from background noise in real time and remembers specific venues, adjusting automatically each time she returns to one. She now hears sounds she hadn't registered in a decade, including her own dishwasher running in the next room.
That kind of adaptive processing is standard across the premium end of the market now:
GN ReSound (Denmark) launched Vivia, marketed as the smallest AI-powered hearing aid available.
Oticon (also Denmark) built "always on" second-generation AI into its new Zeal device.
Cochlear Limited (Australia) went further with its Nucleus Nexa implant system, the first cochlear implant with upgradeable firmware built into the implant itself, so future software improvements no longer require surgery.
Image source: ReSound Vivia
The most experimental work sits at the edges of the device category.
Envoy Medical, based in Minnesota, is running a pivotal trial of Acclaim, a cochlear implant with no external hardware at all: microphone, processor, battery and electrode array sit entirely under the skin, using the natural mechanics of the middle ear instead of an external mic to capture sound. Results are promising but modest: word recognition scores in the trial's first participants rose from a pre-implant baseline of 15.2% to 53.2% at 12 months.
The gap the technology can't close alone
Most of this remains out of reach for the people who need it most.
More than 80% of people with disabling hearing loss live in low- and middle-income countries, where ear and hearing care is often unavailable. In sub-Saharan Africa, hearing aid uptake among people who need one sits below 3%.
The barriers today are mostly workforce and distribution: too few trained audiologists and clinics, and devices still priced for insured markets with a specialist nearby. Two approaches are gaining traction:
Task-shifted fitting. A feasibility study in Khayelitsha, a low-income community outside Cape Town, trained community health workers, not audiologists, to fit over-the-counter hearing aids using smartphone-based tools.
Ultra-low-cost hardware. Devices like LoCHAid have pushed per-unit component costs down dramatically at scale, closer in design to a commodity than a medical device.
The WHO's own contribution is a free smartphone screening app called hearWHO, launched in 2019 and now available in five languages. An academic review of its early rollout recorded well over 240,000 hearing tests taken through the app across dozens of countries in its first two years. It doesn't treat anyone. It takes two to three minutes to tell someone whether they should seek treatment.
Image source: WHO
What actually closes the gap
Miles is expected to grow up hearing normally alongside his siblings. But the therapy that made that possible will reach an estimated 50 children in the US this year. Globally, 1.5 billion people live with some form of hearing loss, and most do not have access to specialist care.
Hearing is one of the more active fields in medicine right now, with new approaches arriving from several directions at once: gene therapy, AI-powered devices, new implant designs, and lower-cost delivery models. Miles's case shows what's possible when a genetic cause is identified early. For the much larger population without that option, progress now depends on all of these advances reaching more people.
Innovation highlights
🔬 AI map for bone marrow. Myelodysplastic neoplasms (MDS) is a blood cancer that's notoriously hard to grade: standard biopsies leave pathologists guessing at how close a case sits to healthy tissue or acute leukemia. Weill Cornell researchers built an AI tool that maps where every bone marrow cell sits and how it's shaped, then compares that architecture to healthy tissue to generate a single severity score. In early testing, the score tracked disease status better than current methods, potentially helping doctors flag patients for more targeted treatment sooner.
🛒 Groceries as a prescription. A randomized trial of 460 Medicaid patients with type 2 diabetes found that weekly deliveries of medically tailored groceries, paired with recipes and phone nutrition counseling, produced an extra 0.4-point drop in HbA1c over six months compared with usual care. The effect held regardless of how much food was delivered. It's some of the strongest evidence yet that treating a grocery bill as part of a treatment plan can measurably improve a chronic disease, not just a patient's pantry.
🕵️ Catching AI's clever shortcuts. Medical AI models can ace their training data for the wrong reasons: one algorithm built to predict a person's sex from eye images turned out to be reading mascara, not biology. Johns Hopkins and the FDA built a tool, G-AUDIT, that scans training datasets before a model is even built, flagging quirks like camera quality or objects that sneak into frame. In one skin cancer dataset, it caught a measuring ruler, included only in high-risk clinic photos, masquerading as a cancer signal.
Cool tool
💉 TempSight, a color-changing label developed at the University of Surrey, UK and now being commercialized with MM Packaging, tracks whether a vaccine vial has been exposed to damaging heat. That addresses a bigger problem than most people realize: as many as half of all vaccines are wasted globally due to breaks in the cold chain, disproportionately in low- and middle-income countries. Until now, the WHO had only one approved vaccine vial monitor technology worldwide.
TempSight is a low-cost alternative now heading into WHO testing before it can be used in international immunization programs, giving health workers a simple visual check for whether a dose is still safe to use.
Weird and wonderful
🧅 Onion fiber, repackaged as willpower. A new food ingredient just cleared the EU's safety bar, and its origin story is delightfully unglamorous: onions and chicory. Scientists at Imperial College London and the University of Glasgow spent 15 years turning fiber from those vegetables into inulin propionate ester, a powder that delivers a fatty acid your gut bacteria already make when digesting fiber, straight to the receptors that tell your brain you're full.
In trials, about 10 grams a day helped people eat less without noticing they were trying. One researcher even called it a food-based alternative to GLP-1 drugs. Turns out the future of appetite control might be sitting in your vegetable drawer.
Image created using Canva AI
Thank you for reading the Healthy Innovations newsletter!
Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.
Have a great week!
Alison ✨
P.S. If you enjoyed reading the Healthy Innovations newsletter, please subscribe so I know the content is valuable to you!
